Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
AEK | Urre jumps. | 30/11/16 | 1 | 1.2K | |||
|
|||||||
AEK | Ann: Merger of URI and Anatolia Energy Approved by Court | 27/11/15 | 3 | 2.4K | |||
|
|||||||
AEK | Ann: Removal From Official Quotation (COB Wednesday 11/09/2015) | 10/11/15 | 0 | 718 | |||
|
|||||||
AEK | Ann: URI Successfully Completes Anatolia Merger | 10/11/15 | 0 | 648 | |||
|
|||||||
AEK | Ann: Quarterly Activities Report | 30/10/15 | 0 | 1.3K | |||
|
|||||||
AEK | Ann: Quarterly Cashflow Report | 30/10/15 | 0 | 990 | |||
|
|||||||
AEK | Ann: ASX Notice - Scheme of Arrangement | 23/10/15 | 0 | 758 | |||
|
|||||||
AEK | Ann: Suspension from official quotation from close of trading | 23/10/15 | 0 | 579 | |||
|
See All Discussions